Abstract: Bone marrow stimulation (BMS) techniques represent the first-line treatment for unstable osteochondral lesions of the talus or after conservative treatment failure. These techniques are intended to penetrate the subchondral bone to elicit bleeding and allow precursor cells and cytokines from bone marrow to populate the lesion. However, the fibrocartilaginous repair tissue arising after marrow stimulation confers inferior mechanical and biological properties compared with the original hyaline cartilage. The limitations of BMS can be overcome by the use of the soluble chitosanbased polymer BST-CarGel (Piramal Life Sciences, Laval, Quebec, Canada). When mixed with freshly drawn autologous whole blood and applied to a lesion surgically prepared by BMS, BST-CarGel acts as a natural bioscaffold that increases the quantity and improves the residency of the blood clot formed in the cartilage lesion, enhancing the local healing response. The use of BST-CarGel has been previously described in the knee and hip joints with successful results. We describe the arthroscopic technique for BST-CarGel application in combination with BMS techniques for the treatment of osteochondral lesions of the talus.
B
one marrow stimulation (BMS) involving microfracture is considered the first-line operative treatment for symptomatic osteochondral lesions of the talus (OLTs) that are 15 mm or less in diameter. BMS has the best reported rate of success in terms of American Orthopaedic Foot & Ankle Society scores. [1] [2] [3] The primary objective of BMS techniques is to penetrate the subchondral bone to allow the subsequent inflow of bone marrow factors, as well as to stimulate pluripotent mesenchymal stem cells of the marrow into the base of the defect. The resultant formation of a fibrin clot triggers a cytokine-mediated inflammatory response that initiates the cascade of tissue healing. Mesenchymal stem cells then differentiate into chondrocyte-like cells that will ultimately form the repair fibrocartilaginous tissue. However, whereas hyaline cartilage consists primarily of type II collagen, fibrocartilage mainly exhibits type I collagen, with inherently different biological and mechanical properties. In addition, fibrillation of the cartilage surface, proteoglycan depletion, and chondrocyte death may result in cartilage degeneration over time. 4, 5 Thus, although fibrocartilage poses an undeniable advantage over exposed subchondral bone as a surface for weight bearing, it has been shown to have inferior stiffness, resilience, and wear properties compared with normal hyaline cartilage. 4 Marrow-derived blood clots formed in the lesion shrink and detach as a consequence of platelet-driven clot retraction. In this sense, Chevrier et al. 6 described that the critical components for BMS cartilage repair are the quantity and the quality of the initial blood clot present in the cartilage lesion.
BST-CarGel (Piramal Life Sciences, Laval, Quebec, Canada) is an implantable/injectable chitosan-based bioscaffold intended to promote hyaline cartilage regeneration when used in conjunction with BMS techniques such as microfracture or drilling for the repair of damaged articular cartilage. Chitosan is a natural polysaccharide derived from deacetylation of chitin, the structural component of the exoskeleton of crustaceans, and is a well studied and biocompatible scaffolding biomaterial because of its low toxicity and its biocompatibility, biodegradability, and adhesiveness to tissues. BST-CarGel is mixed with autologous whole blood and delivered to a surgically prepared cartilage lesion in conjunction with BMS (e.g., microfracture). The BST-CarGeleblood mixture then solidifies/clots in the cartilage defect, forming a gel implant that provides a 3-dimensional scaffold that physically stabilizes the blood clot within the cartilage lesion, impedes blood clot retraction, and facilitates adhesion to its surfaces. The resulting gel implant facilitates the body's own healing response, potentially by enhancing the residency of wound healing factors found in the blood along with bone marrowederived cells. In a multicenter randomized study to evaluate the efficacy of BST-CarGel for repair of focal cartilage lesions in the knee, BST-CarGel treatment resulted in greater lesion filling and superior repair tissue quality compared with microfracture treatment alone at 1 year. 7 An extension to this study was also conducted, and its data permitted the conclusion that these benefits are maintained at 5 years postoperatively. 8 Moreover, it has been shown that BST-CarGel represents a cost-saving alternative to microfracture alone for patients with knee cartilage damage by potentially reducing the risk of clinical events and treatment failure. 9 We describe the technique for the application of BST-CarGel in combination with BMS for the treatment of OLTs.
Surgical Technique
Lesions amenable to arthroscopy are typically chondral and osteochondral lesions with less than 8 to 10 mm in depth and 15 mm in diameter and are normally located in the medial or anterior talar dome. We recommend arthroscopic application of BST-CarGel in combination with BMS for lesion sizes of up to 3 cm 2 in young adult patients (Fig 1) . Treatment with the chitosan-based bioscaffold is contraindicated in patients with any coagulation disorders or those receiving anticoagulant therapy or patients with a known allergy to chitosan or known hypersensitivity to crustaceans such as shrimp, lobster, and crab. Operative treatment indications are summarized in Table 1 .
Ankle arthroscopy is performed with the patient placed in the supine position and without traction. The leg is supported by a well-padded leg holder (Stryker, Kalamazoo, MI), with a tourniquet applied to the upper thigh to work under ischemia conditions. The ankle joint is initially accessed through an anteromedial portal. The surgeon creates the portal by blunt dissection just lateral to the anterior tibial tendon and about 5 mm proximal to the medial malleolus, incising only the skin and avoiding penetration of the subcutaneous tissues. A 4-mm 30 arthroscope (Stryker) is inserted, and the osteochondral lesion is assessed for grade, localization, stability, and size. With the arthroscope in the anteromedial portal, the surgeon creates an anterolateral portal under direct visualization, carefully avoiding damage to the nearby intermediate branch of the superficial peroneal nerve. A limited synovectomy of the anterior chamber is then performed to improve visualization of the joint and to remove inflamed synovium that may contribute to ankle pain and swelling. After synovectomy, resection of the anterior osteophytes is addressed with the aims of eliminating anterior bone impingement (if present) and obtaining better access to the tibiotalar joint. Debridement and curettage are used to address all of the unstable cartilage and fibrous tissue at the base of the lesion and the cartilage that lies immediately adjacent to the defect, creating stable vertical margins to optimize the attachment of the marrow clot that will form after BMS (Fig 2A) . The calcified layer is carefully and completely removed. Once debridement has been accomplished and the healthy vascularized subchondral bone is exposed, the subchondral plate is penetrated to create the bony channels that will communicate with the underlying bone marrow and favor the healing of the lesion (Fig 2B) . Although both nanofracture and standard microfracture can be used to reach the marrow cells, we strongly recommend using the less invasive nanofracture. A nanofracture technique produces smaller and deeper holes, disrupting less surface area and penetrating deeper to reach the bone marrow. This will ultimately result in an increase in cell recruitment, which may positively influence the outcome of the cartilage repair. Nanofracture is performed with an Arthrosurface NanoFx instrument (Arthrosurface, Franklin, MA), producing standardized holes measuring 1 mm in radius and 9 mm in depth. For regular microfracture, arthroscopic awls of different angles (Stryker) can be used to obtain the appropriate perpendicular access to all areas of the prepared lesion. Microfracture holes are placed about 3 to 4 mm apart and 2 to 4 mm in depth. To confirm that BMS has been performed adequately, fat droplets and blood emerging from the subchondral bone should ideally be observed after reduction of the irrigation pressure.
BST-CarGel is prepared according to manufacturer's instructions while the lesion is surgically prepared. In brief, BST-CarGel is made by dissolving an aqueous glycerophosphate buffer in a chitosan solution. To achieve optimal coagulation, the BST-CarGel solution is then pre-warmed at 37 C (body temperature) for 15 minutes. Just before the application, whole peripheral blood is extracted from the patient and mixed with BST-CarGel at a ratio of 3:1 (blood to BST-CarGel). The resulting mixture is then maintained at 37 C until delivery. Before BST-CarGel application, the joint must be completely dried. With the tourniquet still applied to the upper thigh, irrigation is stopped and small swabs and gauzes, introduced through a cannula, are used to completely dry the lesion bed (Fig 2 C and D) . After that, the product is applied, preferably through an 18-gauge needle in a drop-by-drop manner until the defect area is completely filled (Fig 2 E and F) . The mixture volume used per patient varies according to the lesion size. A waiting period of 15 minutes is mandatory until the mixture acquires a more solid consistency and to fully stabilize the implant, before proceeding to the articular mobilization. The key points of the BST-CarGel procedure are shown in Video 1 and summarized in Table 2 .
Postoperatively, the patient must be immobilized for 48 hours. A noneweight-bearing period of 4 weeks is advisable, followed by partial weight bearing until the eighth week after the operation. Full weight bearing is allowed thereafter. Patients may return to sporting activities at a minimum of 4 months after surgery, and high-impact activities are permitted at 9 to 12 months. Hydrotherapy is recommended.
Discussion
The application of BST-CarGel in combination with a BMS technique such as microfracture has been previously reported in the knee and in the hip with successful results. In this report we describe the surgical technique to perform BST-CarGel application for the treatment of OLTs. As stated in this work, application of BST-CarGel in OLTs is safe, is technically feasible, and is not technically demanding. Moreover, the arthroscopic applicability of BST-CarGel represents a clear advantage with respect to more demanding techniques such as autologous matrixinduced chondrogenesis, matrix-induced autologous chondrocyte implantation, mosaicplasty, or synthetic implant application. Data gathered so far suggest that this cartilage repair option could represent an improvement over the standard BMS, overcoming some of its major pitfalls, such as blood clot instability leading to poorquality repair tissue. Nevertheless, long-term follow-up is still unavailable, and these results need to be further confirmed by long-term clinical studies.
